Roche introduces molecular diagnostics system to expand access to testing and improve patient care

SWITZERLAND – Roche has announced the launch of the cobas 5800 System, a new molecular laboratory instrument, in countries that accept the CE mark.

Testing is without a doubt one of the first lines of defense to protect a patient’s normal well-being and is critical in temporarily guiding their treatment.

The cobas 5800 System is poised to assist laboratories deal with the challenges that come with an increase in patient testing, compensation complexities, and the desire for a more extensive testing menu, all while providing significant and timely outcomes.

“Diagnostics continue to revolutionize how providers care for patients, and it is essential, now more than ever, that the healthcare community has access to reliable and accurate testing solutions,” said Thomas Schinecker, CEO Roche Diagnostics.

We are pleased that we can now offer a compact, fully-automated molecular system such as the cobas 5800 System. This new system helps to address the high demands on labs through greater efficiency, optimized workflows and cost savings, enabling them to deliver quality patient care,” he added.

The cobas 5800 device, the most recent member of the Roche Molecular Workplace, is built on the innovation of the cobas 6800 and cobas 8800 programs, bringing molecular testing to more patients worldwide.

The launch comes hot on the heels after Roche announced rocketing sales at its diagnostics division, allowing the company to raise its sales forecast for the year.

The cobas 5800 System is a real-time PCR molecular testing solution with a small footprint that delivers excellent performance and value-added utility. It provides automation, consolidation, integration, and standardization, making it a scalable, cost-effective solution for smaller labs looking for big lab performance or bigger labs looking for small lab agility.

The system is designed to provide a fully automated workflow for sample supply, transfer, and preparation, amplification and detection, result calculation, and delivery to the laboratory information system (LIS).

The single module allows for a walkaway time of up to eight hours, resulting in less hands-on time, which can lead to increased productivity, fewer errors, and more predictable turnaround times.

The menu for the cobas 5800 System will be the same as that for the cobas 6800 and 8800 Systems, including the cobas SARS-CoV-2 test.

The system has a larger on-board capacity, allowing labs to test multiple assays at the same time, and it can produce up to 144 results in an eight-hour shift.

Most labs will be able to consolidate more than 90% of their routine molecular tests onto a single platform thanks to this streamlined molecular testing system.

The single module allows for a walkaway time of up to eight hours, resulting in less hands-on time, which can lead to increased productivity, fewer errors, and more predictable turnaround times.

Roche expects to receive U.S. Food and Drug Administration approval until the third quarter of 2022.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.